Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on NETSCIENTIFIC PLC. We currently have 7 research reports from 2 professional analysts.
|22Feb17 07:00||RNS||Vortex Biosciences Launches VTX-1 Liquid Biopsy|
|30Jan17 07:00||RNS||Grant of Options to Directors|
|18Nov16 07:00||RNS||Netscientific: Vortex Biosciences Analysis Data|
|03Nov16 16:34||RNS||Vortex Gains CE Mark and FDA Class 1 Registration|
|27Sep16 07:00||RNS||NetScientific Interim Results|
|06Sep16 07:00||RNS||Notice of Interim Results|
|03Aug16 07:00||RNS||Vortex Licenses Patents From Harvard University|
Frequency of research reports
Research reports on
Small Cap Breakfast
09 Feb 17
GBGI—Schedule One from the integrated provider of international benefits insurance focused on providing tailored insurance products. Looking to raise £32m with admission expected 22 Feb. Arix Bioscience — Intention to float on the main market from the global healthcare and life science company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.
On deck for multiple 2017 launches
09 Dec 16
NetScientific’s subsidiaries have made multiple advances on regulatory and commercial fronts. ProAxsis and Vortex will both be launching their first products in 2017, and to this end they have both received CE marks for sale in Europe, with Vortex receiving a Class 1 device designation for sale in the US. In addition, Wanda has signed two new contracts with care providers, bringing the total to four.
Transatlantic healthcare technologies
26 Aug 16
NetScientific is a healthcare investment company with a portfolio of digital health, diagnostic, and therapeutic investees. In 2015 the company realigned its investment strategy, bringing a new highly experienced CEO on board, rationalisation of the portfolio and new funding (£18.2m gross from the issue of 15.2m new shares at 120p) to accelerate development in some of its key holdings. A series of value inflection points are expected in 2016 and 2017 including Series A financing for four holdings, the commercial ramp of the Wanda digital health platform, and the launch of the Vortex liquid biopsy product.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017